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Highlights 
 LC-MS/MS method for the determination of 27 opioid analgesics was developed  
 Keeping SPE catridges at -20 oC was the best way to ensure stability of opioids 
 Opioid analgesics are common constituents of municipal wastewater and river water 
 Metabolites of opioids contributed significantly to the overall mass balance  
 Conjugated opioids may represent a significant percentage of the total concentration 
 
Abstract 
Although published literature provides a clear demonstration of widespread occurrence of opioid 
analgesics (OAs) in the aquatic environment, analytical methods suitable for a systematic study of 
this pharmaceutical class, which would include a broad spectrum of opioid analgesics and their 
metabolites, are still missing. In this work, a comprehensive multiresidue method for quantitative 
analysis of 27 opioid analgesics and their metabolites, including 2 morphine glucuronide conjugates, 
was developed and validated for three matrices: raw wastewater (RW), secondary effluent (SE) and 
river water. The method comprised different classes of opioid analgesics, including natural opiates 
(morphine and codeine), their semi-synthetic derivatives (hydrocodone, hydromorphone, 
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oxycodone, oxymorphone and buprenorphine) as well as fully synthetic opioids such as methadone, 
fentanyl, sufentanil, propoxyphene and tramadol. The optimized enrichment procedure involved 
mixed-mode, strong cation-exchange sorbent in combination with a sequential elution procedure. 
The extracts were analyzed by reversed-phase liquid chromatography using a Synergy Polar column 
coupled to electrospray ionization tandem mass spectrometry (LC-MS/MS). Accurate quantiﬁcation 
of target OAs was achieved using 19 deuterated analogues as surrogate standards. Method 
accuracies for RW, SE and river water varied in the range from 91-126%, 74-120% and 75-116%, 
respectively. Careful optimization of the procedure allowed reliable determination of OAs with 
method quantification limits in the low ng/L range (RW: 0.3-2.6 ng/L; SE: 0.2-1.9 ng/L; river water: 
0.1-0.8 ng/L). The developed method was applied for analysis of RW, SE and river water samples 
from Croatia. The concentrations of individual OAs in municipal wastewater varied in a wide range 
(from <MQL to 808 ng/L) and the most prevalent representatives were tramadol, codeine, morphine 
and methadone and their derivatives. Elevated concentrations of morphine glucuronides (up to 459 
ng/L) found in raw municipal wastewater indicated their importance in the overall morphine mass 
balance. 
 
 
Keywords: pharmaceuticals, opioid analgesics, liquid chromatography-tandem mass spectrometry, 
wastewater, surface water 
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1. Introduction 
 
Opioid analgesics (OAs) are a type of prescription drugs, which are used to treat moderate to severe 
pain, particularly of visceral origin. Their mode of action is based on binding to opioid receptors, 
which are found principally in the central and peripheral nervous system and gastrointestinal tract. 
They also find a significant application in heroin addiction treatment. On the other hand, all opioid 
analgesics themselves are well known for their addictive properties and therefore should be 
considered as potential drugs of abuse.  
OAs comprise a number of structurally diverse chemical compounds, such as natural (e.g. morphine 
and codeine), semisynthetic morphine-like opioids (e.g. oxycodone, buprenorphine, ethylmorphin) 
and fully synthetic opioids (e.g. methadone, fentanyl, pentazocine, propoxyphene etc.). Tramadol, 
which was also included in this research, is structurally not an opioid, but does act as one by showing 
agonist activity at the μ-opioid receptor [1].  
The major sources of opioid compounds to the aquatic environment are human excretion and 
dumping of unused medications to the sewer. According to the available pharmacokinetic data [2] 
most of the OAs are extensively metabolized in the human body. Consequently, they are only partly 
excreted as unchanged drugs, while a significant percentage is excreted as metabolites [2]. For 
example, morphine is significantly metabolized after administration. Up to 87% of the dose is 
eliminated in urine with 75% present as morphine-3-glucuronide and only about 10% as unchanged 
morphine. In addition, several minor metabolites such as normorphine, morphine-6-glucuronide, 
diglucuronide, and sulphate conjugate are also formed. Codeine is biotransformed in man via O-
demethylation to morphine and N-demethylation to norcodeine and excreted mainly in conjugated 
form. The metabolism of buprenorphine also leads to the number of products (primarily by N-
dealkylation), which are excreted mainly as conjugated buprenorphine and norbuprenorphine. The 
metabolism of methadone is even more complex. The most important transformation is mono- and 
di-N-demethylation followed by spontaneous cyclisation to 2-ethylidene-1,5-dimethyl-3,3,-
diphenylpyrrolidine (EDDP) and 2-ethyl-5-methyl-3,3,-diphenylpyrrolidine (EMDP). The major urinary 
excretion products are methadone (5-50%) and EDDP (3-25%), while conjugated forms seem to be 
less important. The metabolic pattern of tramadol shows several major products. Approximately 29% 
of an oral dose is excreted as unchanged drug, 20% as free and conjugated O-desmethyltramadol, 
17% as nortramadol and 20% as free and conjugated O-desmethylnortramadol. Since the main 
source of OAs in the environment are municipal wastewater effluents, the human pharmacokinetics 
data clearly show that their metabolic products should be taken into account when assessing their 
behavior and fate in the aquatic environment.  
AC
CE
PT
ED
 M
AN
US
CR
IPT
 4 
 
There have been numerous reports in the literature which addressed the issue of environmental 
occurrence of opioid analgesics. The review by Verlicchi et al. [3] on the occurrence of various 
pharmaceuticals in urban wastewater showed that opioid analgesics, notably codeine and tramadol, 
were among the most abundant compounds. Moreover, codeine was highly ranked regarding 
potential environmental risk. The risk posed by OAs can be significantly enhanced in the watersheds 
influenced by discharges from pharmaceutical formulation facilities [4, 5]. Nevertheless, most of the 
literature published so far dealt only with a limited number of selected representatives of OAs, 
mainly as a part of broader scope studies, aimed to cover several therapeutic classes simultaneously 
[6-8]. Furthermore, OAs have been often included in the studies dealing with sewage epidemiology 
of illicit drugs [9-13] because they themselves have a significant record of abuse. Such studies focus 
primarily on influent wastewater and include only heroin-related metabolites (morphine, 6-
monoacetyl morphine and morphine glucuronide), codeine and methadone along with its main 
metabolite EDDP [9, 11].  
Most of the published analytical methods for the determination of OAs comprise a rather limited 
number of parent compounds and/or their human metabolites [14-19]. The most comprehensive list 
of OAs was covered by a multiresidue LC-MS/MS method developed by Baker and Kasprzyk-Hordern 
[20], who employed solid-phase extraction in combination with ultra-performace liquid 
chromatography-tandem mass spectrometry for wide scope multiclass assessment of 65 
pharmaceuticals and illicit drugs, including simultaneous determination of twenty OAs and their 
metabolites. However, this method does not include some of the most polar representatives of OA-
derived compounds such as morphine derivatives dihydromorphine and hydromorphone and 
especially the two morphine glucuronides. Given the prominence of glucuronide conjugates in the 
human excreta [2], their determination in wastewater might be very important for the correct 
assessment of the total concentration of OAs and thus for the comprehensive assessment of their 
behavior and fate in the aquatic environment. In order to achieve this goal, further improvement of 
analytical methodology is required, especially in terms of improved HPLC separation of polar OAs, 
which include some structurally related isobaric compounds. 
The aim of this study was therefore to develop and validate a dedicated multiresidue LC-MS/MS 
method for simultaneous determination of 27 OAs, which should comprise both parent compounds 
and their major metabolites, including glucuronide conjugates, in environmental aqueous samples. A 
special emphasis was on improvement of chromatographic separation and sample cleanup for a 
more reliable determination of OAs in heavily loaded matrices. In order to improve the overall 
analytical reliability, stability of target compounds during sample preparation and storage was also 
systematically investigated. Finally, the method was applied for determination of opioid analgesics in 
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wastewater and river water samples from Croatia in order to assess their occurrence in the aquatic 
environment, in particular to demonstrate relative importance of so far neglected glucuronide 
conjugates. 
 
2. Experimental 
2.1 Chemicals and materials 
The developed method included 27 analytes, involving both parent compounds and their human 
metabolites, and 19 deuterated analogues used as surrogate standards for quantitation (Table 1). 
Additional information about structures, nomenclature and properties can be found in Table S1 in 
Supplementary material. Standard solutions of all target analytes and their deuterated analogues 
were purchased from Lipomed (Arlesheim, Switzerland) at concentration of 1 mg/mL and 0.1 mg/mL, 
respectively. Mixed standard solutions were prepared in MeOH at concentration of 10 µg/mL for 
analytes and 2 µg/mL for their deuterated analogues, and kept in the dark at -20 °C. LC-MS grade 
methanol and acetonitrile were delivered by BDH Prolabo (UK). Acetic and formic acid, also LC-MS 
grade, and phosphoric acid were purchased from Sigma-Aldrich (Germany). 
Ethylenediaminetetraacetic acid disodium salt dihydrate (Na2EDTA * 2H2O) was also purchased from 
Sigma-Aldrich. 25% ammonia solution in water was supplied by Merck (Darmstadt, Germany). 
Ultrapure water was obtained using an Elix-Milli-Q-system (Millipore, Bedford, USA). Solid-phase 
extraction cartridges, Oasis HLB (200 mg / 6 mL) and Oasis MCX (150 mg / 6 mL) were purchased 
from Waters (Milford, MA, USA), while Strata NH2 cartridges (200 mg / 3 mL) were purchased from 
Phenomenex (Torrance, California, USA). Whatman glass fiber filters (GF/D, 47 mm; pore size, 2.7 
μm) were delivered by GE Healthcare (Maidstone, UK).  
 
2.2 Sample collection and preparation 
All wastewater samples for method optimization and validation, including raw wastewater (RW) and 
secondary effluent (SE) were collected at the central WWTP of the city of Zagreb, while wastewater 
samples for method evaluation were collected in Zagreb and Split. River water samples were 
collected along the Sava River in the city of Zagreb. All wastewater samples were 24 h-composite 
samples, while river samples were grab samples. Sample volumes for RW, SE and river water analyses 
were 125 mL, 250 mL and 500 mL, respectively. After the ﬁltration through glass-ﬁber ﬁlters (GF/D), 
the mixture of surrogate standards (15 ng of each) was added to the samples. The enrichment of 
opioid analgesics from the filtered samples was performed using solid phase extraction (SPE). Two 
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types of SPE cartridges were tested during the method development: Oasis HLB and Oasis MCX. In 
the final procedure, samples were extracted by using Oasis MCX cartridges at pH 2. The pH was 
adjusted by addition of 85% phosphoric acid. The cartridges were previously preconditioned with 5 
mL of MeOH, 5 mL of ultrapure H2O and 5 mL of 25 mM H3PO4 at the ﬂow rate of approximately 5 
mL/min. Before the elution, cartridges were washed with 6 mL of ultrapure water and subsequently 
dried under N2 (30 min). If the samples could not be analyzed on the same day, the cartridges 
containing adsorbed analytes were wrapped up in aluminum foil and stored at −20 °C until analysis. 
The elution of the target opioids from the cartridge was performed using sequential elution. The first 
fraction was eluted with 6 mL of pure MeOH and this fraction, containing only interferences from 
wastewater matrix, was discarded. The second fraction, containing all target OAs, was eluted with 6 
mL of 0.5% NH3 in MeOH. This purified extract was evaporated to dryness under N2 using a TurboVap 
evaporator (Caliper Life Science, Hopkinton, Massachusetts, USA). The residue was redissolved in 500 
µL of H2O/MeOH (8:2, v/v) containing 50 mM ammonium acetate. 
 
2.3 LC-MS/MS analyses 
LC-MS/MS analyses were performed on a instrument (Thermo Electron, USA) consisting of an HPLC 
system equipped with a Surveyor autosampler and a quarternary MS pump interfaced to a triple 
quadrupole mass spectrometer (Quantum AM) equipped with an electrospray ionization source. 
During the method development, four different HPLC columns as well as several different eluents 
and elution gradients were tested. The tested HPLC columns used in this study included Synergi Polar 
(4 µm, 150 mm x 3 mm) and Gemini C18 (5 µm, 150 mm x 3 mm) columns supplied by Phenomenex 
(Torrance, California, USA), YMCPro C18 (3 µm, 150 mm x 2.1 mm) supplied by YMC Europe, 
Schernbeck, Germany and ACE C18-PFP (3 µm, 150 mm x 3 mm) supplied by Advanced 
Chromatography Technologies Ltd (Aberdeen, UK). In the optimized procedure, Synergi Polar column 
was used with 0.1% acetic acid in water (v/v) as eluent A and 0.1% acetic acid in MeOH (v/v) as 
eluent B at the flow rate of 400 µL/min. Gradient elution was performed as follows: 0–20 min, from 
10 to 50% B; 20–21 min, from 50 to 65% B; 21–26 min, from 65 to 85% B; 26–31 min, from 85 to 88% 
B; 31–32 min, from 88 to 95% B; 32–33 min, 95% B (isocratic hold); 33–34 min, from 95 to 10% B; 34–
44 min, 10% B (reconditioning to initial conditions). The injection volume was 15 µL. The target 
analytes were analyzed in positive ionization mode. The capillary voltage was 3500 V and the 
capillary temperature was 300 °C. The desolvation gas (N2) and auxiliary gas (N2) were 40 and 10 
arbitrary units, respectively. Identiﬁcation and quantiﬁcation of target compounds was performed in 
multiple reaction monitoring (MRM) mode, using argon as collision gas. Two most abundant 
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precursor/product ion transitions were selected for each analyte and deuterated surrogate. First 
transition was used for quantification and second for additional confirmation. The collision energy 
and tube lens offset were optimized for each analyte and surrogate separately. The MRM parameters 
for all compounds are presented in Table 1. Quantification of all analytes was performed using the 
corresponding deuterated internal standards. 
 
2.4 Method validation 
The method validation included determination of instrument detection limit (IDL), extraction 
recovery, matrix effect, accuracy, repeatability and method quantification limit (MQL) for each matrix 
(RW, SE, river water) in experiments performed in quadruplicate. 
Linearity range was determined from 12-point internal standard calibration curves obtained by 
injecting standard solutions containing analytes in the concentration range from 0.5 to 1500 ng/mL 
and internal standards at the ﬁxed concentration of 15 ng/mL. Linearity was veriﬁed by F-test, at 95% 
conﬁdence level, according to IUPAC recommendations [21]. Sigma Plot was used for the statistical 
analysis. IDLs were determined by repetitive injection of low concentrations standard solution until 
signal to noise ratio was equal to 3. MQLs were determined as the minimum concentration of target 
analytes in standard solutions that can be measured and fulfilling the following criteria: bias from the 
calibration curve less than 25-30%, peak shapes acceptable, signal to noise ratio at least 8 and RSD of 
four replicates below 19%, taking into account method accuracy and sample volume for each sample 
matrix. 
Extraction recovery was determined from the model experiment in which real water samples were 
spiked with target analytes either before (Abe) or after extraction (Aae). Samples were spiked at 1 
µg/L, 500 ng/L and 50 ng/L for RW, SE and river water, respectively. Analytes already present in the 
original sample were also taken into account (Aorig). The extraction recovery was calculated by 
comparing the average responses of analyte spiked to samples after extraction to the samples spiked 
before extraction according to the following equation: 
 
Extraction recovery (%) = ஺௕௘ି஺௢௥௜௚
஺௔௘ି஺௢௥௜௚
 x 100  
 
The method accuracy was assessed from model experiment in which samples were spiked both with 
analytes and internal standards. Samples were spiked with target compounds at 1 µg/L, 500 ng/L and 
50 ng/L for RW, SE and river water, respectively, while the internal standards were added at 15 ng in 
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all samples. Non-spiked sample was also analyzed to correct for analytes already presented in 
original samples. Accuracy was calculated from the following equation: 
 
Accuracy (%) =  ௖ଶି௖ଵ
௖଴
 x 100  
 
 
where c0, c1 and c2 represent nominal spiked concentration, average concentration measured in 
original sample and average concentration in spiked sample, respectively. 
Repeatability (method precision) was determined in the same experiment and calculated as the 
relative standard deviation (RSD) of the analysis of spiked samples. 
Matrix effect (signal suppression or enhancement) was determined by comparing the average 
response of target analyte spiked in to the final water extracts (Afe), after extraction and evaporation, 
with the average response of analyte in matrix-free standard solutions (Astd) according to the 
following equation:  
 
Matrix effect (%) = ஺௙௘ି஺௢௥௜௚ି஺௦௧ௗ
஺௦௧ௗ
  x 100  
 
In that experiment RW, SE and river water extracts were spiked at the concentration levels of 1 µg/L, 
500 ng/L and 50 ng/L, respectively. Contributions of target analytes from the original sample (Aorig) 
were also taken into account.  
 
2.5 Stability experiments 
Stability of target compounds during storage was studied for three scenarios: a) storage of water 
samples, b) storage of Oasis MCX cartridges after sample enrichment and c) storage of the final 
extracts. 
Stability of opioid analgesics during water sample storage was tested as follows. Raw wastewater 
sample was filtered, spiked at concentration of 1 µg/L and then divided into five identical 
subsamples. One of these subsamples was processed immediately, including SPE, evaporation and 
LC-MS/MS analysis, according to the procedure described in Section 2.2-2.3 (above). Analyses in this 
experiment were conducted in triplicate. The remaining four subsamples were frozen and stored at -
20 °C. These subsamples were processed and analyzed after being stored for 7, 30, 70 and 100 days.  
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Stability of target compounds on Oasis MCX sorbents (cartridges) and in SPE extracts after extraction 
was evaluated as follows. The target analytes were spiked into 800 mL of ultrapure water at the 
concentration of 1 µg/L. The spiked sample was homogenized and divided into 15 subsamples of 50 
mL. In each subsample, deuterated surrogates (15 ng) were also added. All subsamples were acidified 
to pH 2 and extracted on SPE cartridges according to the procedure described in Section 2.2. Three of 
them were eluted, evaporated and analyzed on the same day. The remaining subsamples were 
divided into two sets. The ﬁrst set of MCX cartridges were eluted immediately after the extraction 
and the extracts were frozen at −20 °C until the analysis. The second set of cartridges was kept frozen 
at −20 °C until the day of analysis, when the cartridges were eluted and analyzed. In this experiment, 
the stored samples were analyzed after 7 and 30 days. At each point, the analyses in this experiment 
were conducted in triplicate. 
The results of the stability experiments were analyzed using SigmaPlot software. 
 
 
3. Results and discussion 
 
3.1 LC-MS/MS optimization 
In order to achieve the best chromatographic separation of the selected opioid analgesics, four 
different reverse-phase HPLC columns were tested: Synergy POLAR-RP, YMCPro C18, Gemini C18 and 
ACE C18-PFP. YMCPro C18 and Gemini C18 are reverse phase columns, whose selectivity is mostly based 
on hydrophobic interactions, while the column ACE C18-PFP, which is also strongly hydrophobic, 
contains a specially developed ligand combining a C18 chain with integrated pentafluorophenyl 
functionality. This functionality provides additional π-π interactions as a basis for retention and 
separation of the target compounds. In contrast, Synergi Polar is a polar endcapped, ether-linked 
phenyl phase, which provides both polar and aromatic reversed-phase selectivity.  
Different types of eluents were tested, including water, methanol and acetonitrile as solvents and 
addition of acetic or formic acid as modifiers. Acidic modifier was added to promote protonation of 
basic compounds and increase the MS signal. Formic acid addition (0.1%) to both eluents was 
selected in the optimized procedure. Regarding strong solvent, methanol provided slightly better 
performance than acetonitrile. Preliminary experiments showed that Gemini C18 column was suitable 
only for separation of the most lipophilic OAs, while the hydrophilic OAs (e.g. MOR, glucuronides, 
norMOR) were very poorly retained with very bad peak shapes (Figure S1a, Supplementary info), 
which is probably due to the relatively low carbon load of this column (14%). The alternative C18 
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column YMCPro with carbon load of 16% provided a much better separation of OAs (Figure S1b), 
however some of the isobaric compounds such as morphine and hydromorphone coeluted on this 
column, which precluded their reliable determination. 
On the other hand, ACE C18-PFP column proved to be much more efficient and allowed satisfactory 
separation  and good peak shapes for most of the target compounds (Figure S1c), except for the 
most polar analyte M3G. The best separation with satisfactory retention and peak shapes of polar 
OAs was achieved with Synergi Polar column (Figure 1) and therefore this column was selected for 
further method development. This separation is clearly superior to that shown by Baker and 
Kaszprzyk [20] using a generic method based on BEH C18 column. Of 27 target analytes, there were 
only three co-eluting analyte pairs (DHCOD and OTRA, FNT and BUP and EDDP and PP). However, 
selectivity of the determination for the co-eluting compounds was fully assured by highly specific 
MRM detection, using the two most abundant precursor/product ion transitions for each analyte 
(see Table 1). The first transitions were used for quantification of analytes, while the second 
transitions were used as additional criteria for confirmation. M3G and M6G, which are structural 
isomers with identical product ions, were fully separated on the Synergi Polar column. MRM 
detection provided highly sensitive determination for most of the target OAs, however for some 
analytes, such as NOC, norBUP and PP, the sensitivity was relatively low (IDLs 5-15 pg). In order to 
improve sensitivity, for BUP and norBUP, several product ions were tested, which were previously 
used in literature [12, 17] and the transitions m/z 468 to m/z 396 and m/z 414 to m/z 187 were found 
to be the most sensitive for BUP and norBUP, respectively.  
 
 
3.2 Optimisation of the extraction procedure 
For the optimization of the extraction procedure, two types of SPE cartridges were compared, Oasis 
HLB and Oasis MCX, which have been widely used for the extraction of similar types of basic analytes 
[11, 12, 15, 20, 22]. Besides at the original sample pH (approximately 7.5), Oasis HLB cartridges were 
also tested at basic conditions (pH 10). Basic conditions were chosen to suppress dissociation of the 
target compounds, all of which are weak bases, and in that way to enhance their hydrophobic 
interaction with the sorbent and, consequently, the extraction recoveries. Unlike HLB sorbent, which 
achieves adsorption through hydrophilic and lipophilic interactions, Oasis MCX has a more complex 
mode of retention, involving hydrophobic, hydrophilic and cation-exchange groups. This provides a 
basis for enhanced retention and improves selectivity when extracting basic compounds. The MCX 
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cartridges were tested at pH 2 to promote the interaction of protonated analytes with the cation 
exchange moiety.  
Preliminary experiments, comparing three enrichment procedures described above, were performed 
using spring water spiked with target opioid analgesics and results are presented in Figure S2 
(Supplementary material). Acceptable recoveries (57-115%) were achieved for all target analytes 
using each of the three procedures. The experiment showed that for some analytes, such as codeine 
and tramadol derivatives, better recoveries were obtained using HLB cartridges, especially at pH 10 
(57-115%). In contrast, SFNT showed better recovery on MCX cartridge. Furthermore, this 
experiment demonstrated that most of the target compounds couldn't be completely desorbed from 
the HLB column using pure methanol and therefore an additional elution using 0.5% ammonia 
solution in methanol was required (not shown). The two eluates were analyzed separately and then 
added up to obtain the total concentrations. Based on these preliminary results, HLB enrichment at 
pH 10 seemed to be the most promising procedure.  
However, this could not be verified in a more complex matrix such as wastewater. Firstly, the 
adjustment of pH to 10 in raw wastewater with ammonia solution resulted in the formation of a very 
fine calcium carbonate precipitate, which prevented percolation of the sample due to the cartridge 
clogging. To solve this problem, it was necessary to add high concentration of Na2EDTA (1 g/L) to 
wastewater samples before solid-phase extraction. The comparison of the three SPE protocols for 
the recovery of target compounds from raw wastewater is shown in Figure S3. The recoveries using 
HLB cartridges were similar at pH 10 and pH 7.5, except for EDDP and TRA, whose recovery appeared 
to be much higher at natural pH (7.5). The recoveries of the lipophilic OAs using MCX cartridges were 
only slightly better from those obtained by HLB-based procedure, however for the polar OAs, such as 
morphine glucuronides, OM and HM, MCX showed a clearly superior performance. Morphine 
glucuronides were completely lost during the enrichment using HLB cartridges, indicating problems 
with their retention in complex real matrices.  
Additional problem when using HLB cartridges was co-extraction of some matrix components, which 
caused a significant peak-shape deterioration (Figure 2A). This problem could be rectified only after 
an additional clean up step using aminosilica cartridges as described earlier [23] (Figure 2B). This 
additional step could be skipped when using MCX cartridges for the enrichment (Figure 2C), since this 
procedure applied sequential elution as described earlier [23, 24]. The predominant part of 
interfering compounds was eluted in the methanol fraction, before the final elution of the target 
analytes with 0.5% ammonia solution in methanol.  
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3.3 Method validation 
Method validation parameters, including linearity, instrument detection limits, extraction recovery, 
matrix effect, repeatability and method quantification limits, were determined for three different 
matrices: raw wastewater, secondary effluent and river water, and the results are presented in Table 
2. For most of the analytes, linearity was attained in the range from 0.5 ng/mL to 500 ng/mL with few 
exceptions. For morphine-like opioids, such as norMOR, MOR and DMOR, linearity range was 
narrower (up to 200 ng/mL), while for TRAM and its metabolites linearity range extended up to 1500 
ng/mL. The IDLs varied in wide range from 0.02 pg up to 15 pg (injected on column). MQL were 
generally in the low ng/L range (RW: 0.3-2.6 ng/L; SE: 0.2-1.9 ng/L; river water: 0.1-0.8 ng/L). 
Very good extraction recoveries of OAs were achieved from all three water matrices for most of the 
target OAs (from 79% to 97% for RW, from 73% to 116% for SE and from 73% to 102% for river 
water). Somewhat lower recoveries in raw wastewater were obtained only for EDDP (44%) and TRA 
(63%). For EDDP, some losses were observed during the evaporation step in river water matrix. 
Regarding matrix effects, the experiments showed relatively low effects in all examined matrices. For 
almost all analytes, matrix effects were below 20% with only few exceptions. A slightly more 
pronounced ion suppression (up to 38%) was observed in raw wastewater and river water for early 
eluting polar OAs (M3G, M6G and norMOR) but also for BUP and norBUP. On the other hand, a signal 
enhancement up to 27% was observed for some late eluting OAs (MTHD and SFNT) in the secondary 
effluent extracts. Low matrix effects were probably a result of sequential elution from MCX 
cartridges [23, 24], employing elution with pure methanol (which removed a large percentage of 
matrix components) before the actual elution of the target OAs with basified methanol (0.5% NH3).  
The losses during the sample preparation and matrix effects were successfully compensated using 19 
surrogate standards. For those analytes for which isotopically labelled standards were not available 
(norMOR, M6G, DMOR, norCOD, OTRA, NOC, EMOR and NTRA) the surrogate standard was chosen 
based on the maximum similarity of the chemical structures and retention times. Another criterium 
was also the similarity of the extraction recoveries between the analyte and surrogate, determined in 
preliminary experiments. The morphine derivatives, norMOR and DMOR, were determined based on 
MOR-d3 as surrogate, however, this surrogate was not appropriate for the determination of EMOR. 
Instead, a more closely eluting NFNT-d5 was found more suitable internal standard for EMOR. 
Similarly, the two tramadol derivatives (OTRA and NTRA) were quantified using DCOD-d3 and NFNT-
d5, respectively.  
Careful selection of appropriate surrogate standards allowed determination of all target OAs with 
very good accuracies in all examined matrices (from 80% to 120%). Exceptions were somewhat lower 
accuracies for the determination of norBUP in secondary effluent (74%) and norCOD in river water 
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(75%) as well as for OTRA (126%). It should be stressed that for these compounds deuterated analogs 
were not available in this work. 
The analytical repeatability of the target analytes was better than 11% for all matrices. The only 
exception was repetability of EDDP determination in raw wastewater (15%), which was probably 
related to lower recoveries of this compound (44%). 
Overall, our analytical quality assurance parameters compare very well with the best literature 
achievements [20], while providing analysis of an extended range of OAs. 
 
3.4 Stability of opioid analgesics in samples 
Stability of opioid analgesics in wastewater samples during sample storage and analysis is an 
essential part of accurate assessment of these compounds in real systems. Losses of target 
compounds during storage can lead to a significant underestimation of the true concentrations, while 
formation from co-occurring precursors would lead to an overestimation of the target compounds. 
Among selected opioid compounds, both options are very likely [25-27]. When analyzing large 
number of samples collected in a sampling campaign, which cannot be processed on the same day, 
there are two strategies to minimize possible pitfalls due to the sample deterioration: immediate 
storage of the samples by freezing at low temperature (typically -20 °C) or extraction of the samples 
on the same day with options to store either adsorption cartridges or the final extract until 
instrumental analysis. In this work, stability of the target opioid analgesics was examined for raw 
wastewater, which is the most complex matrix regarding possible biotic and abiotic processes. 
Determination of stability of OAs during wastewater sample storage at -20 °C showed that some 
analytes were stable even during prolonged storage time of 100 days with only slight changes in 
concentrations, which didn’t exceed 20% (Table 3). On the other hand, for some analytes such as 
SFNT, PP, FNT, norBUP, NFNT, NTRA, EMOR, NOC, HM and NHC, a statistically significant decrease of 
concentrations (>25%) was observed already after 7 days. A gradual decrease for EMOR, NFNT and 
BUP continued during the prolonged storage of 100 days. The most unstable opioid compounds were 
morphine glucuronides and 6-AM, which is in accordance with our earlier observations [26]. The loss 
of glucuronides exceeded 50% after 30 days and the concentration continued to decrease till the end 
of experiment. It should also be noted that M3G was significantly less stable than M6G. Similarly, the 
concentration of 6-AM decreased by 86% on the day 100. It is interesting that decrease of M3G, M6G 
and 6-AM was accompanied by a significant increase in the concentration of MOR (up to 195% after 
100 days). This shows that transformation between these analytes can occur during prolonged 
storage. 6-AM is an exclusive biomarker of heroin, so its stability in wastewater samples is essential 
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for a reliable estimation of heroin consumption using wastewater-based epidemiology approach. Our 
results show that estimation of heroin consumption based on 6-AM might be underestimated, if the 
samples were kept frozen before extraction. In addition, norBUP, also increased during the 
experiment, while its precursor BUP decreased. 
Comparison of OAs stability on the MCX cartridges and in the SPE extracts stored at -20 °C after 
extraction of target compounds is presented in Figure 3. Most of the opioid analgesics were found to 
be stable on MCX cartridges over a period of 30 days (loss <20%). A moderate, statistically signiﬁcant 
decrease of the concentrations (up to 31%) was observed for norMOR, DMOR, MOR and HC. Only for 
M6G and EDDP a more pronounced concentration loss (up to 43%) was noticed, however the 
difference between the days 7 and 30 was not significant. A significant decrease in OA concentration 
in SPE extracts was observed for 6-AM (43%), EMOR (42%), DMOR (49%) and 6-morphine 
glucuronide (56%). Generally, opioid analgesics were more stable if the MCX cartridges were stored 
at -20 °C after SPE rather than SPE extracts. The stability of opioids during storage of SPE cartridges at 
-20 °C was also demonstrated by Baker and Kasprzyk-Hordern [25], who reported that OAs, adsorbed 
onto MCX cartridges, were stable over a period of 6 weeks, and Gonzalez-Marino et al. [28], who 
showed that OAs adsorbed onto HLB cartridges were stable for three months. Consequently, storage 
of MCX cartridges was selected as the best way to preserve the samples after extraction and to avoid 
sample alterations. 
 
3.5 Method application 
The developed method was applied for the analysis of target opioid analgesics in real samples, 
including raw water, secondary effluent and river water, collected in the area of the cities of Zagreb 
and Split (Croatia). The results are presented in Table 4. The measured concentrations of individual 
opioids varied in wide ranges, from <MQL (low ng/L) to almost 1 µg/L. The most abundant opioid 
compounds were TRA and its metabolites NTRA and OTRA with the total concentration in WW 
exceeding 1 µg/L. It is interesting to note that TRA metabolites contributed significantly to the total 
concentration. This is in agreement with published literature [6, 7, 15]. Other relatively abundant 
opioid compounds found in untreated municipal wastewater included COD (237-625 ng/L), MOR 
(142-445 ng/L), M3G (4-370 ng/L), M6G (5-89 ng/L), MTHD (71-94 ng/L) and its metabolite EDDP 
(115-175 ng/L). Such results are not surprising since tramadol and codeine belong to the widely 
prescribed opioid analgesics for the treatment of moderate-severe pain in Europe [29]. On the other 
hand, MOR and its glucuronide conjugates originate mainly from the heroin abuse, while only a 
smaller part (10-15%) is associated with the therapeutic use [7, 30]. Although literature data often 
suggest that morphine glucuronides are quickly deconjugated by wastewater bacteria and biofilms 
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[31], our data from Split show that contribution of conjugated MOR can reach up to 50% of the total 
MOR concentration calculated on the molar basis. This indicated that the contribution of conjugated 
morphine must be taken into account when assessing the total morphine in municipal wastewater as 
a basis for the estimation of heroin consumption. Alternatively, heroin consumption can be 
estimated using 6-AM as exclusive heroin biomarker, and therefore, it is important to emphasize that 
the developed method allows its reliable measurement in low ng/L concentrations. 
Moreover, in addition to its use as analgesic, the presence of MTHD and its metabolite EDDP can be 
related to extensive use of MTHD for the treatment of heroin addiction in Croatia. Other opioids, 
found in measurable concentrations, were norMOR, 6-AM and BUP, while most of the other semi-
synthetic OAs were not detected. It is interesting to note that the concentration of BUP (3-11 ng/L) 
was much lower than that of MTHD and EDDP, indicating that its use for the treatment of heroin 
addiction is less popular in Croatia.  
It is interesting to note that the concentrations of OAs in secondary effluents were in the same range 
as those in raw wastewater, indicating that conventional biological wastewater treatment was rather 
inefficient in removing these compounds from wastewater. Lack of any removal was observed for 
TRA and its derivatives and methadone, while the removal efficiencies of COD and MOR were 21-28% 
and 65-67%, respectively. The elimination of minor opioids 6-AM and BUP were 50-67% and 20-43%, 
respectively. These ﬁndings are in a good agreement with our previously published data [11] and the 
recent literature [7, 20]. The only opioid which was efficiently eliminated in conventional WWTP was 
norMOR (>90%). 
As could be expected, considering a relatively large dilution factor (typically >50), the concentrations 
of OAs in the Sava River were rather low (<MQL-72 ng/L) with prevalence of those compounds which 
were the most abundant opioid constituents in municipal wastewater (TRA, NTRA, OTRA, COD and 
EDDP). This could be primarily result of dilution since the results on removal efficiency in WWTP 
indicated that these compounds are rather refractory to biodegradation. The measured 
concentrations are lower than those reported by Baker and Kasprzyk-Hordern [20], probably as a 
combined result of lower usage prevalence and a high dilution factor in the Sava River. 
 
4.0 Conclusions 
The developed analytical method allows reliable determination of 27 opioid analgesics and their 
metabolites at trace concentrations in different aqueous matrices thus providing a basis for their 
comprehensive study in the aquatic environment. Application of the method to real wastewater and 
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river water samples showed widespread occurrence of OAs in the aquatic environment. Inclusion of 
the number of OA metabolites along with their parent compounds indicated that the relative 
contribution of metabolites to the overall mass balance could be significant, which has often been 
neglected in literature. In particular, we showed that conjugated OAs may play an important role. 
Results showed that opioid analgesics and their metabolites can reach significant levels in municipal 
wastewaters, raising concerns about their possible ecotoxic effects. The method is expected to be an 
important tool for systematic monitoring of OAs and assessment of their behavior and fate in the 
aquatic environment as well as for wastewater-based epidemiology to study their potential abuse. 
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FIGURE CAPTIONS 
 
Figure 1. MRM chromatogram of standard mixture of opioid analgesics (100 pg/uL). HPLC column: Synergi Polar (4 µm, 150 mm x 3 mm). For abbreviations 
of analyzed substances see Table 1. 
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Figure 1. MRM chromatogram of standard mixture of opioid analgesics (100 pg/µL). HPLC column: Synergi Polar (4 µm, 150 mm x 3 mm). For abbreviations 
see Table 1. 
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Figure 2. MRM chromatogram of raw wastewater extract spiked with target opioid analgesics (1 µg/L) obtained on:  A) Oasis HLB cartridges without extract 
clean up; B) Oasis HLB cartridges with extract clean up on Strata NH2   and C) Oasis MCX cartridges by fractionated elution. For abbreviations see Table 1. 
 
 
 
Figure 2. MRM chromatogram of raw wastewater extract spiked with target opioid analgesics (1 µg/L) obtained on: A) Oasis HLB cartridges without extract 
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Figure 3. Stability of opioid analgesics (spiking level: 1 µg/L, n=3) stored on Oasis MCX cartridges and in SPE extracts at -20 °C for 7 and 30 days. For 
abbreviations of analyzed substances see Table 1. 
 
 
 
Figure 3. Stability of opioid analgesics (spiking level: 1 µg/L, n=3) during storage after their extraction on to Oasis MCX cartridges and in SPE extracts during 7 
and 30 days (T= -20 °C). For abbreviations see Table 1.
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Table 1. List of opioid analgesics analysed in this study and the applied LC-MS/MS parameters. 
Common name Abbreviation Internal standard 
RT 
(min) 
Precursor ion 
(m/z) 
Product ion 1 
(m/z) 
CE (1) 
/ V 
Product ion 2 
(m/z) 
CE (2) 
/ V 
Morphine-3-β-D-glucuronide M3G M3G-d
3
  4.1 462 286 27 201 41 
Normorphine norMOR MOR-d
3
  5.6 272 165 44 201 25 
Morphine-6-β-D-glucuronide M6G MOR-d
3
  6.5 462 286 35 201 36 
Dihydromorphine DMOR MOR-d
3 
 6.9 288 185 35 187 31 
Morphine MOR MOR-d
3
  7.4 286 165 42 201 27 
Oxymorphone OM OM-d
3
 8.3 302 284 20 227 29 
Hydromorphone HM HM-d
3
 9.2 286 185 29 157 40 
Norcodeine norCOD COD-d
3
  11.2 286 165 37 225 17 
Dihydrocodeine DCOD DCOD-d
3
  12.2 302 199 27 201 25 
O-desmethyl-cis-tramadol OTRA DCOD-d
3 
 12.2 250 58 20 232 12 
Codeine COD COD -d
3
 12.8 300 165 37 215 20 
Noroxycodone NOC NOC-d
3 
 13.2 302 284 15 187 23 
Norhydrocodone NHC NHC-d
3
 13.8 286 199 26 183 38 
Oxycodone OC OC-d
6
  14.1 316 298 17 187 27 
6-acetylmorphine 6-AM 6-AM-d
3
 14.4 328 165 34 211 23 
Hydrocodone HC HC-d
3
  14.8 300 199 28 183 27 
Ethylmorphine EMOR  NFNT-d
5
 16.1 314 229 24 183 27 
Norfentanyl NFNT NFNT-d
5
 16.7 233 84 17 177 13 
Tramadol TRA  TRA-O-CD
3
 18.5 264 58 14 246 10 
N-desmethyl-cis-tramadol NTRA NFNT-d
5 
 19.0 250 44 15 232 9 
Norbuprenorphine norBUP norBUP-d
6 
 24.1 414 187 39 211 45 
Fentanyl FNT FNT-d
5 
 25.5 337 188 24 105 32 
Buprenorphine BUP BUP-d
6
  25.5 468 396 45 187 45 
EDDPa EDDP EDDP-d
3
 26.1 278 234 31 249 23 
Propoxyphene PP PP-d
5 
 26.1 340 266 8 58 13 
Sufentanil SFNT SFNT-d
5 
 26.5 387 238 19 110 35 
Metadone MTHD MTHD-d
3 
 27.2 310 265 14 105 26 
Morphine-3-β-D-glucuronide -d3 M3G-d3 - 4.1 465 289 29 204 38 
Morphine-d3 MOR- d3 - 7.3 289 165 37 201 24 
Oxymorphone -d3 OM- d3 - 8.2 305 287 19 230 27 
Hydromorphone -d3 HM- d3 - 9.2 289 185 32 157 43 
Dihydrocodeine -d3 DCOD- d3 - 12.1 305 201 31 199 32 
Codeine -d3 COD- d3 - 12.7 303 165 37 215 25 
Norhydrocodone -d3 NHC- d3 - 13.7 289 202 29 183 30 
Oxycodone -d6 OC- d3 - 14.0 322 304 20 190 29 
6-acetylmorphine -d3 6-AM- d3 - 14.3 331 165 38 210 24 
Hydrocodone -d3 HC- d3 - 14.7 303 199 32 183 28 
Norfentanyl -d5 NFNT- d5 - 16.6 238 84 25 56 27 
Tramadol –O-CD3 TRA-O-CD3 - 18.3 267 58 16 249 9 
Norbuprenorphine-d6 norBUP- d6 - 24.1 417 211 43 188 23 
Fentanyl -d5 FNT- d5 - 25.5 342 188 23 105 34 
Buprenorphine -d6 BUP- d6 - 25.6 472 400 45 59 45 
EDDP-d3 EDDP- d3 - 26.0 281 237 28 249 20 
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Propoxyphene -d5 PP- d5 - 26.1 345 271 7 58 7 
Sufentanil -d5 SFNT- d5 - 26.6 392 238 19 111 35 
MTHD-d3 MTHD- d3 - 27.1 313 268 12 105 30 
CE – collision energy, RT –retention time 
a2-Ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine 
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Table 2. Method validation parameters for the determination of opioid analgesics in raw wastewater, secondary effluent and river water (spiking level: 1 µg/L for RW, 
500 ng/L for SE, 50 ng/L for river water; n=4). 
 Raw wastewater (RW) Secondary effluent (SE) River water  
 
Linearity 
range r
2 IDL (pg) R 
Extraction 
recovery 
Matrix 
effect Accuracy MQL R 
Extraction 
recovery 
Matrix 
effect Accuracy MQL R 
Extraction 
recovery 
Matrix 
effect Accuracy MQL 
    (%) (%) (%) (%) (ng/L) (%) (%) (%) (%) (ng/L) (%) (%) (%) (%) (ng/L) 
M3G 0.5-500 0.999 0.4 4 90 -25 111 0.3 2 78 -18 109 0.2 3 82 -38 94 0.1 
norMOR 0.5-200 1.000 0.2 3 89 -27 102 0.9 4 82 -11 106 0.5 5 81 -25 80 0.2 
M6G 0.5-500 0.999 1 1 89 -17 119 0.7 11 73 -9 96 0.4 4 79 -24 82 0.2 
DMOR 0.5-200 0.999 0.07 4 92 -15 124 1.0 1 84 -5 119 0.6 4 86 -9 107 0.3 
MOR 0.5-200 0.997 0.1 3 95 -21 125 0.9 4 79 -7 109 1.1 5 73 -13 100 0.3 
OM 0.5-500 0.999 1 2 91 -16 117 0.3 4 81 -8 114 0.2 3 87 -15 98 0.1 
HM 0.5-500 0.999 0.05 4 88 -28 110 2.6 3 81 -8 100 1.7 7 90 -16 98 0.8 
norCOD 0.5-500 0.999 0.3 2 92 -12 106 1.8 4 84 5 113 1.1 4 85 -15 75 0.4 
DCOD 0.5-500 0.999 0.3 2 93 -1 120 2.8 1 85 4 112 1.5 3 87 2 95 0.7 
OTRA 0.5-1500 0.999 0.02 3 97 1 126 0.4 5 79 -6 93 0.2 3 87 3 98 0.1 
COD 0.5-500 1.000 0.1 2 91 -7 116 0.4 2 81 -15 102 0.2 3 91 0 83 0.1 
NOC 0.5-500 0.998 5 2 89 -9 105 2.5 5 81 8 100 1.5 3 85 -11 91 0.6 
NHC 0.5-500 1.000 0.07 2 88 -6 104 1.1 3 84 15 107 0.7 3 92 -16 86 0.3 
OC 0.5-500 0.999 1 1 90 4 115 0.4 6 88 10 120 0.2 3 89 -2 98 0.1 
6-AM 0.5-500 0.998 0.2 3 93 -11 119 0.4 5 93 8 118 0.2 4 102 -8 94 0.1 
HC 0.5-500 0.994 0.08 1 88 -5 107 1.1 3 86 4 101 0.6 4 96 -8 100 0.3 
EMOR 0.5-500 0.999 0.02 2 91 -4 115 3.5 1 88 6 120 1.9 11 87 -5 116 0.8 
NFNT 0.5-500 0.999 0.05 4 91 2 120 0.8 4 84 20 111 0.5 6 86 -3 94 0.2 
TRA 0.5-1500 1.000 0.3 8 63 -4 106 1.2 5 83 -16 79 0.5 4 92 7 101 0.3 
NTRA 0.5-1500 1.000 0.05 3 92 0.2 116 1.2 6 87 5 103 0.6 3 87 1 93 0.3 
norBUP 0.5-500 0.998 5 4 91 -26 113 0.6 4 86 5 74 0.4 3 87 -13 89 0.2 
FNT 0.5-500 0.999 0.04 3 90 -12 114 0.4 6 89 18 120 0.2 7 87 0 97 0.1 
BUP 0.5-500 0.995 0.4 1 86 -31 115 0.3 8 87 2 114 0.2 2 84 -10 98 0.1 
EDDP 0.5-500 0.999 0.08 15 44 -9 104 0.7 4 116 7 109 0.4 0 109 1 103 0.2 
PP 0.5-500 0.999 15 2 79 -19 108 0.6 5 89 14 109 0.5 4 90 -1 99 0.2 
SFNT 0.5-500 0.997 0.06 3 89 -4 108 0.8 5 91 27 117 0.5 4 93 -3 98 0.2 
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MTHD 0.5-500 0.997 0.1 6 79 -8 91 2.6 4 90 24 110 1.7 2 89 3 102 0.7 
For abbreviations see Table 1.  
IDL - instrumental detection limit. MQL - method quantification limit; R – repeatability  
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Table 3. Stability of opioid analgesics in raw wastewater sample (spiking level 1 µg/L; n = 3) during 
sample storage at -20 °C. 
 
Residual percentage (%) 
 
7 days 30 days 70 days 100 days 
M3G 40* 38* 1* 0* 
norMOR 84* 92* 114* 112 
M6G 55* 28* 45* 32* 
DMOR 85* 74* 76* 83* 
MOR 118* 139* 183* 195* 
OM 79* 90* 100 88* 
HM 76* 90* 80* 71* 
norCOD 83* 103 111 119 
DCOD 79* 106 95 85* 
OTRA 79 120 130* 96 
COD 83 95 105 118 
NOC 72* 86 112* 78* 
NHC 66* 96 112 97 
OC 79* 89* 93 89* 
6-AM 70* 59* 29* 14* 
HC 78* 79* 83* 60* 
EMOR 85* 65 60* 69* 
NFNT 75* 50* 60* 53* 
TRA 91* 88* 91 59 
NTRA 78* 98 96* 76 
norBUP 73* 70* 97 78 
FNT 72* 84* 87* 70* 
BUP 67* 59* 57* 57* 
EDDP 82* 103 89* 80 
PP 74* 82* 92* 79* 
SFNT 76* 79* 87* 73* 
MTHD 80* 87* 99 78 
For abbreviations see Table 1. 
*Signiﬁcant change (t-test; p < 0.05). 
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Table 4. Occurrence of opioid analgesics in raw wastewater (RW), secondary effluent (SE) and river water in Croatia. 
c (ng/L) 
OA RW-ST-1
a 
(24/08/2016) 
RW-ST-2a 
(09/11/2016) 
RW-ZG-1b 
(21/03/2017) 
RW-ZG-2b 
(24/03/2017) 
SE-ZG-1b 
(21/03/2017) 
SE2b 
(24/03/2017) 
River water 1c 
(23/03/2017) 
River water 2c 
(23/05/2017) 
M3G 296 370 5.0 4.0 <MQL <MQL <MQL <MQL 
norMOR 26 16 21 23 <MQL <MQL 1.8 <MQL 
M6G 65 89 5.0 5.0 <MQL <MQL <MQL <MQL 
DMOR 6.2 <MQL <MQL <MQL <MQL <MQL <MQL <MQL 
MOR 445 287 148 142 52 47 <MQL 0.3 
OM <MQL <MQL <MQL <MQL <MQL <MQL <MQL <MQL 
HM <MQL <MQL <MQL <MQL <MQL <MQL <MQL <MQL 
norCOD <MQL <MQL <MQL <MQL <MQL <MQL 1.6 <MQL 
DCOD <MQL <MQL <MQL <MQL <MQL <MQL <MQL <MQL 
OTRA 671 298 624 671 859 890 10 7.6 
COD 237 625 400 478 289 379 4.0 1.1 
NOC <MQL <MQL <MQL <MQL <MQL <MQL 2.0 <MQL 
NHC <MQL <MQL <MQL <MQL <MQL <MQL 2.8 <MQL 
OC <MQL <MQL <MQL <MQL <MQL <MQL <MQL <MQL 
6-AM 24 30 3.1 1.9 1.0 0.9 <MQL <MQL 
HC <MQL <MQL <MQL <MQL <MQL <MQL <MQL <MQL 
EMOR <MQL <MQL <MQL <MQL <MQL <MQL <MQL <MQL 
NFNT <MQL <MQL <MQL <MQL <MQL <MQL <MQL <MQL 
TRA 717 586 748 752 808 721 23 72 
NTRA 189 135 208 214 246 249 5.3 4.2 
norBUP <MQL <MQL <MQL <MQL <MQL <MQL 1.8 <MQL 
FNT <MQL <MQL <MQL <MQL <MQL <MQL <MQL <MQL 
BUP 11 3 4.9 7.1 4.1 3.9 <MQL <MQL 
EDDP 175 115 159 148 176 182 1.7 0.9 
PP <MQL <MQL <MQL <MQL <MQL <MQL <MQL <MQL 
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SFNT <MQL <MQL <MQL <MQL <MQL <MQL <MQL <MQL 
MTHD 94 73 71 76 65 64 <MQL <MQL 
 
For abbreviations of analyzed opioid analgesics (OA) see Table 1.  
MQL - method quantiﬁcation limit; acity of Split; b Wastewater treatment plant of the city of Zagreb; c Sava river 
 
 
 
AC
CE
PT
ED
 M
AN
US
CR
IPT
